Table 4.
Outcome of older (≥60 years) AML patients
| 2000–2004 | 2005–2009 | 2010–2014 | P | |
|---|---|---|---|---|
| N = 133 | N = 163 | N = 167 | ||
| Day-60 death, n (%) | 21 (15.8) | 27 (16.6) | 17 (10.2) | 0.196 |
| CR1, n (%) | 89 (66.9) | 107 (65.6) | 125 (74.9) | 0.150 |
| Induction failure, n (%) | 23 (17.3) | 30 (18.4) | 23 (13.8) | 0.498 |
| Allo-SCT in CR1, n (%) | 0 | 7 (6.5) | 24 (19.2) | <0.001 |
| Auto-SCT in CR1, n (%) | 0 | 2 (1.9) | 0 | 0.187 |
| CR2, n (%) | 10/60a (16.7) | 12/70a (17.1) | 13/65a(20) | 0.868 |
| Allo-SCT in CR2 | 0 | 0 | 5 (38.5) | 0.007 |
| Clinical trial, n (%) | 51 (38.3) | 38 (23.3) | 54 (32.3) | 0.018 |
| Median DFS, months (IQR) | 14.3 (5.1–52) | 14.2 (6.7–44) | 12.7 (6.3-NR) | 0.945 |
| Median OS, months (IQR) | 12.1 (3.3–36) | 12.3 (3.8–39) | 16.1 (5.9–52) | 0.256 |
CR1 first complete response, CR2 second complete response, DFS disease-free survival, IQR interquartile range, OS overall survival, SCT stem cell transplantation
aRelapses after CR1